Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A in a Gel Applied in Patients That Performed Radical Prostatectomy
Biozeus Biopharmaceutical S.A.
72 participants
Nov 22, 2023
INTERVENTIONAL
Conditions
Summary
To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Daily oral administration of tadalafil 5mg
Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
Oral administration of a placebo pill
Topical application of 1.5 mL of placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05558007